De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

OssDsign Beheer

Beheer criteriumcontroles 2/4

De CEO OssDsign's is Morten Henneveld, benoemd in Sep2020, heeft een ambtstermijn van 4.08 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 7.94M, bestaande uit 54% salaris en 46% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.2% van de aandelen van het bedrijf, ter waarde SEK 1.32M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 5.8 jaar.

Belangrijke informatie

Morten Henneveld

Algemeen directeur

SEK 7.9m

Totale compensatie

Percentage CEO-salaris	54.0%
Dienstverband CEO	4.1yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	3.9yrs
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

Jun 19

Recent updates

OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 23

We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth

Aug 06

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

Jun 19

Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely

Mar 19

Here's Why We're Not Too Worried About OssDsign's (STO:OSSD) Cash Burn Situation

Aug 19

Analyse CEO-vergoeding

Hoe is Morten Henneveld's beloning veranderd ten opzichte van OssDsign's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-SEK 114m
Mar 31 2024	n/a	n/a	-SEK 118m
Dec 31 2023	SEK 8m	SEK 4m	-SEK 130m
Sep 30 2023	n/a	n/a	-SEK 109m
Jun 30 2023	n/a	n/a	-SEK 95m
Mar 31 2023	n/a	n/a	-SEK 99m
Dec 31 2022	SEK 6m	SEK 4m	-SEK 99m
Sep 30 2022	n/a	n/a	-SEK 96m
Jun 30 2022	n/a	n/a	-SEK 93m
Mar 31 2022	n/a	n/a	-SEK 95m
Dec 31 2021	SEK 6m	SEK 6m	-SEK 94m
Sep 30 2021	n/a	n/a	-SEK 90m
Jun 30 2021	n/a	n/a	-SEK 92m
Mar 31 2021	n/a	n/a	-SEK 90m
Dec 31 2020	SEK 1m	SEK 1m	-SEK 85m

Compensatie versus markt: De totale vergoeding ($USD 773.19K ) Morten } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 253.61K ).

Compensatie versus inkomsten: De vergoeding van Morten is gestegen terwijl het bedrijf verliesgevend is.

CEO

Morten Henneveld (48 yo)

4.1yrs

Tenure

SEK 7,939,000

Compensatie

Mr. Morten Henneveld has been Chief Executive Officer at OssDsign AB (publ) since September 1, 2020. Mr. Henneveld serves as a Director at Sime Diagnostics Ltd., since October 2022. He is Senior Vice Presi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Morten Henneveld	Chief Executive Officer	4.1yrs	SEK 7.94m	0.20% SEK 1.3m
Anders Svensson	Chief Financial Officer	3.9yrs	geen gegevens	0.085% SEK 545.6k
Tom Buckland	Chief Technical Officer	less than a year	geen gegevens	geen gegevens
Melanie Marshall	Vice President of Clinical & Medical Affairs	2.8yrs	geen gegevens	geen gegevens
Eric Patermo	Vice President of Sales US	4.8yrs	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van OSSD wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Viktor Drvota	Independent Director	9.8yrs	geen gegevens	geen gegevens
Newton Aguiar	Independent Director	5.8yrs	SEK 250.00	0.10% SEK 656.9k
Simon Cartmell	Independent Chairman of the Board	8.5yrs	SEK 350.00	0.13% SEK 822.5k
Jill Schiaparelli	Independent Director	2.3yrs	SEK 250.00	geen gegevens
Christer Fahraeus	Director	less than a year	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van OSSD wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

OssDsign Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

OssDsign AB (publ), Annual General Meeting, May 21, 2024

High number of new directors

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

Recent updates

OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings: EPS misses analyst expectations

We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

No longer forecast to breakeven

Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

New minor risk - Share price stability

Forecast breakeven date moved forward to 2024

OssDsign AB (publ), Annual General Meeting, May 21, 2024

Consensus EPS estimates fall by 30%, revenue upgraded

Forecast breakeven date moved forward to 2024

OssDsign AB (publ.) Announces 12-Month Data from the Clinical Study Top Fusion

OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024

OssDsign AB (publ) Reports Exceptional Data from the Clinical Study TOP FUSION

Ossdsign AB (Publ) Provides Revenue Guidance for the Fourth Quarter of 2023

An Unknown buyer acquired 7.6% stake in OssDsign AB (publ) (OM:OSSD).

OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 150.000003 million.

OssDsign AB (publ) Announces All Activities Pertaining to the Patient-Specific Cranial Implant Business Will Be Discontinued in A Responsible Manner by the End of December 2023

OssDsign Receives FDA Clearance for A New Major Indication

Consensus EPS estimates fall by 15%

Consensus estimates of losses per share improve by 14%

Second quarter 2023 earnings released: kr0.30 loss per share (vs kr0.40 loss in 2Q 2022)

Here's Why We're Not Too Worried About OssDsign's (STO:OSSD) Cash Burn Situation

Forecast breakeven date moved forward to 2024

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

OssDsign AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023

Forecast to breakeven in 2025

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.63568 million.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity

High number of new directors

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to kr14.00

Insufficient new directors

Consensus revenue estimates fall by 16%

Chief Executive Officer recently bought kr133k worth of stock

Chief Executive Officer recently bought kr133k worth of stock

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

OssDsign AB (publ), Annual General Meeting, Jun 02, 2022

Insufficient new directors

OssDsign AB (publ.) Receives Approval to Establish Clinical Registry in the U.S. to Collect Real-World Data on OssDsign Catalyst

Forecast to breakeven in 2024

OssDesign AB (Publ.) Announces Updated Clinical Data from A Long-Term Follow-Up of the Company's Innovative Product OssDsign Cranial PSI, Which Is Used in the Treatment of Cranial Bone Defects

Chief Executive Officer recently bought kr124k worth of stock

Third quarter 2021 earnings released: kr0.30 loss per share (vs kr1.10 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr1.30 loss in 2Q 2020)

Independent Chairman of the Board recently bought kr150k worth of stock

Consensus EPS estimates increase to -kr3.00

Price target decreased to kr17.33

Chief Executive Officer recently bought kr210k worth of stock

Chief Executive Officer recently bought kr388k worth of stock

Ossdsign AB (Publ) Announces Innovative Synthetic Bone Graft Outperforms a Comparable Device in Bone Formation Following Spinal Fusion Surgery

Chief Financial Officer recently bought kr214k worth of stock

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 240.506091 million.